BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 3:52:00 PM | Browse: 867 | Download: 510
Publication Name World Journal of Gastroenterology
Manuscript ID 7508
Country Romania
Received
2013-11-22 08:43
Peer-Review Started
2013-11-22 19:42
To Make the First Decision
2014-01-20 14:28
Return for Revision
2014-01-20 15:38
Revised
2014-01-25 06:32
Second Decision
2014-02-20 09:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-20 09:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-04-22 09:11
Publish the Manuscript Online
2014-05-07 10:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Case Report
Article Title Ulcerative colitis worsened after Clostridium difficile infection: Efficacy of infliximab
Manuscript Source Invited Manuscript
All Author List Andrada Seicean, Anca Moldovan-Pop and Radu Seicean
Funding Agency and Grant Number
Corresponding Author Andrada Seicean, MD, PhD, Regional Institute of Gastroenterology and Hepatology, Iuliu Hatieganu University of Medicine and Pharmacy, Strada Croitorilor 19-21, Cluj-Napoca 400162, Romania. andradaseicean@gmail.com
Key Words Clostridium difficile; Ulcerative colitis; Inflammatory bowel disease; Trough level; Infliximab
Core Tip Clostridium difficile infection (CDI) in patients with ulcerative colitis (UC) can worsen the disease and increase the risk of colectomy and death, thus requiring an escalation of treatment. This report reveals a case of UC worsened by recurrent CDI, which likely activated the patient’s immune response and stimulated the relapse of UC. Lack of response to infliximab therapy was indicated by low trough levels, and a high-dose infliximab regimen yielded better clinical results. Infliximab trough levels were found to correspond with patient outcome, and thus may serve to guide treatment in similar cases of UC with CDI.
Publish Date 2014-05-07 10:10
Citation Seicean A, Moldovan-Pop A, Seicean R. Ulcerative colitis worsened after Clostridium difficile infection: Efficacy of infliximab. World J Gastroenterol 2014; 20(17): 5135-5140
URL http://www.wjgnet.com/1007-9327/full/v20/i17/5135.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i17.5135
Full Article (PDF) WJG-20-5135.pdf
Full Article (Word) WJG-20-5135.doc
Manuscript File 7508-Review.docx
Answering Reviewers Format for Answering Reviewers (1).docx
Copyright License Agreement BPG Copyright Assignment.pdf
Non-Native Speakers of English Editing Certificate Editing_Certificate_20131121210253.jpg